Document is current

Article History

Received: 4 October 2024

Accepted: 24 October 2024

First Online: 17 November 2024

Competing interests

: B.A.B. receives research support from the National Institutes of Health (NIH) and the US Department of Defense, as well as research grant funding from AstraZeneca, Axon, Corvia, Novo Nordisk and Tenax Therapeutics. B.A.B. has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT and VADovations and is named inventor (US patent no. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat HF. M.R.Z. receives research support from the Department of Veterans Affairs and serves as a consultant for Abbott, Adona Medical, Aria CV, Avery Therapeutics, Inc., Boehringer Ingelheim, Boston Scientific, Cardiovascular Research Foundation (CRF) Clinical Trials Center, CVRx, DIASTOL Therapeutics, LLC, EBR, Edwards, Lilly, GenKardia, Innoventric, Kestra Medical, Medtronic, Merck, Morphic Therapeutics, Novartis, Pulnovo, Salubris Biotherapeutics, Sonata, sRNAlytics Inc., V-WAVE and Vectorious. C.M.K. has served as a consultant for Eli Lilly. S.J.B. has served as consultant for Altimmune, Amgen, Beren Therapeutics, Boehringer Ingelheim, Lilly, Esperion, Ionis Pharmaceuticals, Madrigal Pharmaceuticals, Merck, Novartis and Regeneron. S.E.L. reported being on the patient selection committee for Corvia and Axon and being a consultant for Novo Nordisk and Lilly. K.H., M.M., Y.O. and N.U. are employed by Eli Lilly and Company. M.P. has served as a consultant for 89bio, AbbVie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Lilly, Imara, Medtronic, Moderna, Novartis, Pharmacocosmos, Reata, Regeneron, Roche and Salamandra.